You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued ProductDequalinium dichloride (Cat. No. 0674) has been withdrawn from sale for commercial reasons.
A potent and selective non-peptide blocker of the apamin-sensitive small conductance Ca2+-activated K+ channel (IC50 = 1.1 mM).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Dunn (1994) Dequalinium, a selective blocker of the slow afterhyperpolarization in rat sympathetic neurones in culture. Eur.J Pharmacol. 252 189 PMID: 8157060
View Related Products by Product Action
Keywords: Dequalinium dichloride, Dequalinium dichloride supplier, K+, channel, blockers, SKCa, Potassium, Channels, BKCa, Maxi-K, sAHP, ca2+-activated, ca2+-dependent, Ca2+-Activated, 0674, Tocris Bioscience
Citations for Dequalinium dichloride
Citations are publications that use Tocris products.
Currently there are no citations for Dequalinium dichloride.
Reviews for Dequalinium dichloride
There are currently no reviews for this product. Be the first to review Dequalinium dichloride and earn rewards!
Have you used Dequalinium dichloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.